Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations
Joint Authors
Dhall, Rohit
Morgan, John C.
Rubens, Robert
Khanna, Sarita
Gupta, Suneel
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-10-22
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD).
Following an initial peak at about one hour, plasma LD concentrations are maintained for about 4-5 hours.
Objective.
To present dosing factors that may affect the successful conversion to ER CD-LD from other LD formulations.
Methods.
Two-phase 3 studies of ER CD-LD vs.
immediate-release (IR) CD-LD (ADVANCE-PD) and vs.
CD-LD + entacapone (CLE; ASCEND-PD) in subjects with advanced PD included a 6-week, open-label conversion to ER CD-LD prior to treatment randomization.
The “converted” daily LD dose ratio and dose frequency for ER CD-LD were compared to the prior LD treatment regimens at study entry.
Results.
The average daily LD dose ratio at the end of dose conversion to ER CD-LD was approximately 2.1 for IR CD-LD and 2.8 for CLE.
The final dose ratios tended to be slightly higher for participants taking lower LD doses at study entry but independent of dose frequency.
ER CD-LD dose frequency increased with increasing LD dose and dose frequency at study entry.
Participants on higher baseline LD doses ≥800 mg and dose frequencies ≥6 tended to have higher rates of discontinuation during conversion to ER CD-LD.
Conclusions.
Converting participants from other LD formulations to ER CD-LD is based on their current LD regimen.
For the most common daily doses (≤1250 mg) and dose frequencies (<7) of LD, final mean dose ratios were within tight ranges of 2.1 to 2.4 for IR CD-LD (ADVANCE-PD) and 2.4 to 2.8 for CLE (ASCEND-PD) and were generally independent of the LD dosing frequency at study entry.
These trials are registered with NCT00974974, NCT01130493.
American Psychological Association (APA)
Morgan, John C.& Dhall, Rohit& Rubens, Robert& Khanna, Sarita& Gupta, Suneel. 2018. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations. Parkinson’s Disease،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1212500
Modern Language Association (MLA)
Morgan, John C.…[et al.]. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations. Parkinson’s Disease No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1212500
American Medical Association (AMA)
Morgan, John C.& Dhall, Rohit& Rubens, Robert& Khanna, Sarita& Gupta, Suneel. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations. Parkinson’s Disease. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1212500
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1212500